Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 6/20 | 0.48 |
| ▸ | CTSS | P25774 | 6/20 | 0.44 |
| ▸ | CTSK | P43235 | 5/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ACE | P12821 | 2/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7228964 | 0.88 | ACE (0.55) | CTSSCTSKACECTSLCTSB | |
| SCHEMBL20045974 | 0.82 | PPARG (0.53) | CTSSCTSKCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL14803767 | 0.82 | PPARG (0.53) | CTSSCTSKCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL7260689 | 0.81 | CTSS (0.63) | CTSSCTSKCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL920111 | 0.81 | CTSS (0.63) | CTSSCTSKCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3823172 | 0.80 | KLK5 (0.48) | CACNA1BCTSSCTSKACECTSL | |
| SCHEMBL5887691 | 0.80 | CTSS (0.64) | CACNA1BCTSSCTSKCYP1A2CYP2C9 | |
| SCHEMBL1111230 | 0.80 | CTSS (0.50) | CTSSCTSKCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL13913373 | 0.80 | CTSS (0.50) | CTSSCTSKCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5312993 | 0.80 | CTSS (0.50) | CTSSCTSKCYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180099005-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | HOFFMANN-LA ROCHE, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099005-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | ITGB1, ITGA4, ITGB4 | CACNA1B 99/4885CTSS 3453/4885CTSK 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.